Recombinant Mouse IgG1 Isotype Control Antibody

Recombinant mouse IgG1 isotype control mAb against E. coli β-galactosidase

InvivoGen provides a recombinant anti-β-Gal-mIgG1 monoclonal antibody (mAb)  that was previously extracted from hybridoma. It is now expressed and produced in chinese hamster ovary (CHO) cells, ensuring reliability and lot-to-lot reproducibility. Thereby, common hybridoma-related drawbacks such as the generation of non-relevant mAbs containing aberrant light chains are avoided. This control antibody targets E. coli's β-galactosidase (β-Gal), an antigen that is not present in mice. In addition, it displays low ADCC (antibody-dependent cell-mediated cytotoxicity) and no CDC (complement-dependent cytotoxicity) effector functions [1].

The sequence of Anti-β-Gal-mIgG1 is 100% murine (constant and variable regions), as the original clone (clone T9C6) was raised in mice using a proprietary method. This feature allows for reduced immunogenicity and risks of fatal hypersensitivity reactions upon repeated mAb injections into mice [2].

InvivoGen provides this antibody in two grades:

• In vitro use: Anti-β-Gal-mIgG1
• In vivo use: Anti-β-Gal-mIgG1 InvivoFit™

Key features:

• Targets E. coli β-galactosidase antigen
• Sequence is 100% murine
• Murine IgG1 isotype (constant region)
• Free from non-relevant mAbs found in hybridoma-based productions
• Produced in animal-free facilities and defined media
• Low aggregation < 5%
• InvivoFit™ grade is available

References:

1. Bradbury, A. et al., 2018. When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions. mAbs, 10(4), 539–546.
2. Yamazaki T. et al., 2005. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 175(3):1586-92.